Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × sapacitabine × 90 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Specimen Handling 156 pembrolizumab 152 Magnetic Resonance Spectroscopy 137 Carboplatin 113 Cyclophosphamide 102 Biopsy 98 Nivolumab 92 Cisplatin 89 Paclitaxel 82 Radiotherapy 78 Gemcitabine 72 durvalumab 66 atezolizumab 64 Dexamethasone 61 Bevacizumab 57 Rituximab 54 Radiation 54 Lenalidomide 51 Doxorubicin 50 venetoclax 49 Pemetrexed 49 Docetaxel 48 Prednisone 47 fludarabine 46 Oxaliplatin 46 Ipilimumab 45 olaparib 44 Vincristine 43 Fluorouracil 41 Etoposide 41

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03641755 2026-02-23

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

Dana-Farber Cancer Institute

Phase 1 Active not recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡